Introduction
Pressure, in terms of the economic aspects of epilepsy, has been increasing in both wealthier and poorer nations. In the richer countries, an ongoing argument continues regarding how to control the steady growth in health care expenditure. The inflation of needs is a dilemma that it is pressuring the state-financed health care system. Therefore, emphasis is placed on finding the best means to minimize the costs of health care. Alternatively, poorer countries are experiencing a large need for health care but with insufficient resources. The irregular allotment of epilepsy care among countries, and sometimes within countries, does not greatly match the actual requirements but, to a certain extent, does match the underlying economic condition. 1 In fact, about 80% of all health expenditure occurs in developed countries, while the remaining 20% of economic resources is spent in the rest of the world, where approximately 90% of the individuals with epilepsy reside. 2 Thus, it is imperative to think about the economic aspects of the disease to improve the situation of patients in all areas of the world. It is essential to recognize that epilepsy is not a standardized disorder, but rather the term describes several clinical situations that exhibit the symptom of an epileptic seizure. When assessing the requirement for care and the services available, it is common that policy-makers (i.e., governments or insurance agents) do not differentiate between the various types of epilepsy. Economically, a high level of discrepancy may exist in the costs of being an epileptic patient, according to the frequency, severity, and type of seizure. Oftentimes, epilepsy is associated with a primary disorder that may persist even after remission of the seizures, such that not all expenses or costs may be attributable to epilepsy. 1, 3 Along these lines, the International League Against Epilepsy (ILAE) replaced the old terms idiopathic, symptomatic, and cryptogenic with modified conceptual terms genetic, structural-metabolic, and unknown. 4 The term refractory epilepsy may not be comparable among different studies or settings, owing to the different assessment criteria that may be adopted. However, more consistent figures can be attained when patients are selected based on the new concept (i.e., etiology). The term symptomatic, which was replaced by structural-metabolic, is often substituted for the concept of a poor prognosis or a challenging type of patients. 4, 5 Up to date, none of the published cost studies were specifically focused on patients diagnosed with structural-metabolic epilepsy. [6] [7] [8] [9] [10] [11] [12] [13] The focus of current investigation is to estimate the first-year medical care costs of newly diagnosed children with structuralmetabolic epilepsy and to determine the cost-driving factors in the selected population.
Materials and methods

Setting
The study was conducted at the pediatric neurology clinic, Hospital Pulau Pinang. This hospital is the main public hospital in Penang Island. It is a tertiary referral center for the Northern Territory, Peninsular Malaysia. At present, Hospital Pulau Pinang has 3293 employees, with 115 specialists and 412 medical officers. It has 1090 beds, covering a catchment area of approximately 750,000 people. 14 
Study design
A retrospective chart review was implemented. It was an annual prevalence-based economic evaluation on patients attended the Pediatric Neurology Clinic, Hospital Pulau Pinang. The total first-year medical care costs were estimated from the provider (i.e., hospital) perspective, using a bottom-up, microcosting analysis. Medical chart/billing data obtained from the hospital were collected to determine the resources used. Prices or cost data were standardized for the year 2010 (One Malaysian Ringgit MYR is equivalent to 0.26 Euro or 0.32 USD).
All patients who satisfied the following criteria were included: (a) age !2 years; (b) newly diagnosed with structural-metabolic (symptomatic) epilepsy based on clinical, electrophysiological, and imaging investigations; (c) therapeutic management with antiepileptic drugs (AEDs); (d) three or more visits during the first year from the referral time; and (e) received all of their medical care at the Pediatric Neurology Clinic, Hospital Pulau Pinang. The recruited children were followed for one year following the first visit.
The exclusion of patients <2 years of age was rationalized by the considerable changes of physiological parameters during the first two years of life. Pediatric patients cannot be considered as one homogeneous population. There are significant differences in physical, cognitive and psychosocial development. Infants and toddlers (28 days to 23 months) have rapid mental, physical and immune development. More to the point, drugs elimination may exceed that in children >2 years of age. In that sense, there is a huge variability in medication response, as the development does not occur at the same rate in all pediatric patients. 15 A comprehensive screening process of all medical records at the Pediatric Neurology Clinic, Hospital Pulau Pinang was carried out.
This screening targeted all patients who attended the clinic in the past to the time of conducting the study. More than 1200 medical records were screened, and only 255 files of them were belonged for patients diagnosed with epilepsy. However, based on the adopted inclusion criteria, only 132 patients were suitable to be incorporated into this study. Medical records of the patients were reviewed for information on patient's demographic, clinical characteristics, and resource utilization.
Manpower costs
To estimate the costs of each service or intervention utilized by the recruited patients, an activity-based costing (ABC) approach was employed. Accordingly, staff and/or head departments were interviewed to determine the activities of each service or intervention. Subsequently, a time-motion study was conducted to estimate the costs of human resources. This was done by measuring the time spent by staff to perform one single activity several times using a stopwatch. The monthly salary for each of the involved employees was measured according to the pay scale of the Federal Civil Services Officers under the System of Remuneration Malaysia. 16 By assuming a daily working time of 8 h and a monthly working time of 28 days, these monthly salaries were converted into the cost or salary per minute (MYR/min). The mean time (minute) spent by employees doing a specific activity was multiplied by the salary per minute (MYR/min). Ultimately, the total manpower cost incurred for a service or intervention was the sum of human resource costs of all activities involved in producing it.
Capital costs
The costs of furniture, and clinical and non-clinical machines were obtained from the procurement section of each department. However, some of these clinical machines were not purchased by the hospital. Companies provided the machines to the hospital at no cost (as reagent-rentals), but it is obligatory for the hospital to buy consumables from the same providing companies. To keep consistent with other Malaysian hospitals that do not adopt the reagent-rentals approach and to enhance the generalizability of the results, the costs of these reagent-rental machines were acquired from the same providing companies, assuming that Hospital Pulau Pinang bought these machines rather than reagentrented them.
The costs of the building were calculated by multiplying the area of space in square feet by MYR 85, which represented the cost of one square foot, according to the Hospital Pulau Pinang Development Office. Total capital costs were the sum of equivalent annual costs of all assets involved in the intervention/service. Then, the asset cost per sample/patient was the product of dividing total capital costs by the total number of samples/patients exposed to that particular intervention/service in the year 2009. Along these lines, several assumptions were made. The useful life of a clinical machine was assumed to be five years, whereas for furniture and the building, the useful life was considered to be 10 and 30 years, respectively. 17 Moreover, straight-line deprecation with a discount rate of 3% was assumed. At the end of the asset's useful life, the resale value was considered to be 10% of the initial costs. 18 
Consumable costs
Generally, data were collected as annual expenditure on consumables for the year 2009, which was subsequently divided by the total number of samples/patients receiving the service or intervention. Many of these figures were gathered from the billing data of the related department or by interviewing staff and/or head departments. Nevertheless, inclusive information about consumable expenditure was already available for the majority of laboratory tests conducted in the pathology department.
Medication costs
All drugs prescribed to the patients were included and categorized as AEDs and non-AEDs. The drug unit costs were based on the cost of acquisition of drugs by Hospital Pulau Pinang and multiplied with the patient's individual daily dose and duration of therapy.
Hospitalization costs
The daily cost of hospitalization as a consequence of seizure relapse or breakthrough seizure was based on the tariff by the Planning and Development Division, Ministry of Health, Malaysia. 19 The costs of medications, laboratory tests, therapeutic drug monitoring (TDM) tests, and diagnostic investigations were not considered during the period of hospitalization as they were already included in the tariff. The total cost of each admission was the length of hospital stay (day) multiplied by MYR 286.
Estimation of the total intervention/service costs
Finally, the cost of each intervention/service was the sum of total manpower costs, total capital costs, and total consumable costs. However, the types of cost elements included may vary from one intervention/service to another. The cost of pediatric neurology clinic was completely based on manpower costs, whereas the costs of electroencephalogram (EEG), radiological investigation, laboratory tests, and TDM were based on the three major elements (manpower, capital, and consumables).
Statistical analysis
Demographic and clinical characteristics of the patients were analyzed by descriptive statistics. Normality of continuous variables were tested by the nonparametric one-sample Kolmogorov-Smirnov test (K-S test). All of the continuous variables were non-normally distributed. Mean AE SD and percentiles (25-50-75) were calculated for the continuous variables. Percentages and frequencies were used for the categorical variables. Comparison of a continuous variable between two groups was done by MannWhitney test. The Kruskal-Wallis test was applied to determine the differences of continuous variables among !3 groups. The nonparametric Spearman's rho test was applied to test the correlation between two continuous variables.
Lastly, the relationships between a continuous dependent variable (first-year medical care costs) and other independent variables (patient's seizure frequency, type of AEDs, therapy type, child development, type of seizure, TDM utilization) were further examined by multiple regression analysis. Variables were entered into the regression models simultaneously. All of the analyses were performed by using the PASW (Predictive Analytics SoftWare) Statistics 18.0.
Results
Patients' description
One hundred thirty two patients were recruited in this study and 12 of them were excluded because of missing/ambiguous data and doubt associated with the etiology of epilepsy. The mean age of the studied patients was 7.23 AE 3.55 years with males slightly (59%) higher than females (41%). With respect to racial distribution, three groups of patients were identified (Chinese, 42.5%; Malays, 32.5%; and Indians, 25.0%). The proportions of patients with generalized (53%) and focal (47%) seizures were almost comparable. During the followup period, two-thirds of the patients received only old generation AEDs (valproic acid, carbamazepine, clonazepam, phenobarbital, and phenytoin) and only one-third of the patients received the newer agents (lamotrigine, topiramate, vigabatrin, and gabapentin) as adjuvant therapy. The baseline and last follow-up visit seizure frequency were 34.37 AE 116.96 and 14.59 AE 34.74 attacks per month, respectively.
Resource utilization
For the 120 patients studied, a total of 563 outpatient clinic visits were recorded. Twenty-nine in-patient admissions were documented among the studied sample. The length of hospital stay was 2.93 AE 4.22 days. During the investigated period, 54% of the patients received EEGs (only one patient had 2 EEGs). Fourteen patients were investigated by magnetic resonance imaging (MRI), and only 4 children received ultrasound (U/S). Thirty-two patients received TDM services throughout the follow-up period. Fifty assays were done for those TDM patients; eight were done during admissions, and 42 tests were performed during outpatient clinic visits. Approximately two-thirds of the patients did not have any laboratory tests, whereas 240 tests were performed for the rest of the children (Table 1) .
Medical care costs
For the 120 patients studied, the cost of outpatient clinic visits was MYR 7974.33, while the cost of hospitalization was MYR 24,310 ( Table 2 ). The cost of EEG was MYR 2876.47, whereas the cost of MRI was MYR 5390.50, and the cost of U/S was MYR 87.22. The total first-year medical care cost for 120 patients with structural-metabolic epilepsy was MYR 202,816 (i.e., MYR 1690.13 per patient per year).
Cost driving factors
Based on the univariate analysis, the first-year medical care costs showed no significant difference between global developmental delay/intellectual disability (GDD/ID) patients and normally developed patients (Table 3) . Similarly, the variation in cost was quite small between children with focal seizures and others with generalized seizures. In contrast, the difference in cost between patients utilizing monotherapy and polytherapy was significant (p < 0.001). Moreover, patients who received TDM services had higher management costs than those who had not received TDM services (p = 0.01). Likewise, children who received the new generation AEDs as adjunctive therapy generated higher costs than those who continued on old generation AEDs alone (p < 0.001). None of the demographic variables (i.e., gender, race, and age) showed any significant effect or impact on the first-year medical care costs. Statistical analysis demonstrated a significant correlation between the patient's seizure frequency (attacks per year) and the first-year medical care costs (r s = 0.294, p = 0.001). With respect to the multivariate analysis (Table 4) , all tolerance values went above 0.1; likewise, the variance inflation factor (VIF) values were also well below the threshold mark of 10. Both of these figures signified that interpretation of the regression coefficients was not influenced by multi-collinearity. The model fit the data well (R 2 = 0.292, F = 7.772, p < 0.001). The only variable that significantly influences the first-year medical care cost was the type of AEDs. In that way, the relation between seizure frequency and type of AEDs was also examined. Patient's seizure frequency (attacks per year) was significantly (p < 0.001) higher in patients received new generation of AEDs as add on therapy (42.82 AE 95.63) than those who received only old generation of AEDs (13.35 AE 31.62).
Discussion
In the present study, the cost of outpatient clinic visits constituted only a small proportion (3.93%) of the total medical care costs. This was totally compatible with the findings of a prospective economic evaluation in Italy. The cost of medical consultations in the first year of management for newly diagnosed children made up 3.68% of the total cost of management. 8 In contrast, a retrospective follow-up analysis in Hong Kong showed that the cost of outpatient visits represented 39% of total expenditures on epilepsy management. 9 This can be rationalized by the exclusion of the cost of laboratory tests, radiological investigations (e.g., CT scan), and EEG in the above-cited study.
With respect to a developing country like India, the cost of outpatient clinic visits accounted for 8.85% of the total expenditure on epilepsy management. 10 Unlike the current investigation, questionnaires were used to gather the required data from patients in the cited Indian study. Thus, patients with major neurological disabilities were excluded from the study. In that sense, this value may not be comparable with the present findings. In this study, the cost of hospitalization accounted for 12% of the total expenditure on epilepsy management. By searching the literature, the proportion of admission costs showed a wide range of variation among different studies. [6] [7] [8] [9] [10] [11] [12] [13] 20 In Italy, a cost study on newly diagnosed children with epilepsy demonstrated that hospital admission and day hospital represented the main cost of epilepsy during the first year of management. 8 Likewise, hospitalization made up around 50% of the first-year costs of refractory epilepsy in newly diagnosed adults. 20 This huge discrepancy can be attributed to the differences in the selected population between these cited studies and the current study. Further, a study from Oman showed that 52% of the cost of epilepsy management was due to hospitalization. 11 On the other hand, statistics from other developing countries, such as India (8.48%) and Burundi (22.3%), to some extent demonstrated comparable findings to the current study. 10, 12 In the present study, the cost of diagnostic procedures (e.g., U/S, MRI, and EEG) and laboratory tests made up only a small proportion (8.07%) of the total medical care costs. Consistently, the cost of investigative procedures and tests in newly diagnosed epileptic children was only a small proportion of the first-year costs of management. 8 In the United States, diagnostic procedures and tests constituted about 12% of total cost of management in newly diagnosed adults with epilepsy. 20 Likewise, findings from a retrospective multi-center study in India showed that only 7.3% of the total cost of epilepsy management was related to investigations. 10 Returning to the present study, only 1.15% of the total expenditure on epilepsy management was spent on TDM. This was consistent with results of a prospective observational study in Oman, in which only 1% of the total expenditure on epilepsy management was related to the assessment of plasma AED levels. 11 In Hong Kong, a retrospective cohort study showed that approximately 1.9% of total cost of epilepsy management was attributed to TDM. 9 Hence, the proportion of TDM cost in this study was quite similar to that found in other studies. In this study, AEDs were the most expensive cost element, constituting approximately 70% of the total medical care costs. Studies from developed countries, including the United Kingdom, the United States, Italy, and Hong Kong, showed figures contradictory to those from this study. [6] [7] [8] [9] 20 In these cited studies, the proportion of AED cost ranged from 10% to 34% of the total cost of epilepsy management. Further, findings from a developing country (Oman, 22.5%) were incompatible with that of the present study. 11 On the other hand, the cost of AEDs comprised 57.7% of the total cost of epilepsy management in a retrospective study in India. 10 In one of the above-cited studies, the average daily dose was used to estimate the cost of AEDs. 7 Another study was based on published literature and/or an expert panel of physicians. 20 By comparing these figures with that of the present study, the cost of AEDs was individualized, and a micro-costing approach was adopted. Moreover, most of the mentioned studies were not conducted on pediatric populations. In addition, none of the stated studies were exclusively based on patients newly diagnosed with structural-metabolic epilepsy. These issues may explain the huge discrepancies in the cost proportion of AEDs between this study and the published literature. In this study, the first-year medical care costs were not significantly different among various demographic variables (i.e., gender, race, and age). Likewise, Child development, seizure type, therapy type (i.e., polytherapy versus monotherapy), and TDM utilization had no impact on the total medical care costs. However, the cost was significantly influenced by the use of new AEDs as add-on therapy.
Consistent with the present findings, a retrospective study from Burundi illustrated that cost was not associated with gender, age, or seizure type. 12 In a similar manner, a study from a developed country (Germany) found that age, gender, and type of epilepsy had no influence on the cost of epilepsy. 13 In contrast, in Oman, a prospective observational study revealed a significant positive association between age and cost. 11 Further, higher cost was observed for patients with generalized seizures than patients with partial seizures. The findings of this cited study were obviously inconsistent with that of the current investigation. The study included patients aged !13 years, while the current study focused on children aged !2 years. Therefore, this conflict between the two studies might be attributed to the disparity in the age of the recruited patients. The high cost associated with the use of new AEDs was expected. This was supported by the findings of a previous study conducted at the same clinic. 21 The use of lamotrigine as one of the new AEDs led to 103% increase in the medication costs. In the present study, seizure frequency was found to be associated with the first-year medical care costs. This relationship between seizure frequency and cost was reported earlier by several studies. 7, 13, 22, 23 In this investigation, patients who received new AEDs had higher seizure frequency and cost than patients who only received the old AEDs. In that sense, the type of AEDs used is the most influential variable on the medical care costs. In this study, selecting patients based on seizure diagnostic scheme or underlying type of cause (etiology) may have some novelty compared with previous studies. However, this study has a number of limitations that must be addressed. The retrospective evaluation of data taken from medical records has many weaknesses which have restricted the adoption of the incidence-based approach. There was a great deal of unclear or missing data, mostly for the epilepsy and seizure type. Hence, patients were excluded if they had poor documentation or missing data.
Although a micro-costing approach was adopted for the current investigation, the application of gross costing in estimating the cost of hospitalization may undervalue the actual expenses of several patients. For instance, children with status epilepticus may require intensive care.
Conclusion
This investigation was the first cost analysis study of epilepsy in Malaysia. The total first-year medical care costs for 120 patients with structural-metabolic epilepsy were MYR 202,816 (i.e., MYR 1690.13 per patient per year). The study findings highlight the importance of optimizing seizure control in reducing the cost of management.
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